IP Library Granted Patent US 11,261,239
Granted Patent B2
US 11,261,239 · App. 15/678,798 · Granted Mar 1, 2022

RSV F protein compositions and method for making same

Inventors: Kurt Swanson (Newton, MA); Philip R. Dormitzer (Weston, MA)
Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
C07K16/1027A61K39/12A61K39/155C07K14/005A61K39/00A61K2039/5252A61K2039/5256A61K2039/5258A61K2039/53A61K2039/55505A61K2039/55555A61K2039/55561A61K2039/55566A61K2039/55572C07K2317/76C07K2319/00C07K2319/21C07K2319/50C07K2319/73C12N2760/18522C12N2760/18534C12N2770/36143
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,261,239
App. No.
15/678,798
Granted
Mar 1, 2022
Kind
B2
Abstract

The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F proteins. Compositions prepared using the methods can contain RSV F protein ecto-domain polypeptides in a predominant or single desired form and conformation. The invention also relates to methods for inducing an immune response to RSV F.

Claims (3)

1. An immunogenic composition containing a recombinant polypeptide that comprises a first domain and a second domain, wherein (i) the first domain comprises the respiratory syncytial virus F (RSV F) protein ectodomain, and (ii) the second domain comprises SEQ ID NO: 19.

2. The immunogenic composition of claim 1 , wherein the recombinant polypeptide is in the form of a monomer, trimer, rosette or any combination thereof.

3. The immunogenic composition of claim 1 , further comprising an adjuvant selected from the group consisting of: an aluminum salt, a squalene-in-water emulsion, a benzonapthyridine compound, a phospholipid compound, a small molecule immunopotentiator and combinations of any of the foregoing.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 6, 2022
From: SWANSON, KURT; DORMITZER, PHILIP R
To: NOVARTIS VACCINES & DIAGNOSTICS, INC.
Reel/Frame 058572/0390 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 6, 2022
From: CHIRON CORPORATION
To: NOVARTIS VACCINES & DIAGNOSTICS, INC.
Reel/Frame 058572/0472 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 6, 2022
From: NOVARTIS AG
To: GLAXOSMITHKLINE BIOLOGICALS SA
Reel/Frame 058573/0564 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 6, 2022
From: NOVARTIS VACCINES & DIAGNOSTICS, INC.
To: NOVARTIS AG
Reel/Frame 058585/0660 →
Continuity (4)
Continuation 12836931 · Jul 15, 2010
Provisional Application 61294426 · Jan 12, 2010
Provisional Application 61225805 · Jul 15, 2009
Related Publication 20200172600A1 · Jun 4, 2020